AB 554, the Protecting Rights, Expanding Prevention, and Advancing Reimbursement for Equity (PrEPARE) Act of 2025, aims to cut administrative and financial barriers to antiretroviral products used to prevent HIV. The measure confines plans’ ability to impose utilization management and requires broader coverage and pharmacist dispensing and reimbursement for prophylactic services.
For professionals: the bill alters how plans and insurers manage and pay for preexposure prophylaxis (PrEP), postexposure prophylaxis (PEP), and other FDA-approved antiretroviral prevention products — potentially changing formularies, benefit design (medical v. pharmacy), pharmacy practice revenue, and compliance risk for delegated PBMs and carriers.
At a Glance
What It Does
The bill bars health plans and insurers from subjecting FDA‑approved antiretroviral drugs, drug devices, and drug products used to prevent HIV to prior authorization or step therapy, with a narrow exception when at least one therapeutically equivalent product is already covered without those controls. It requires coverage without cost sharing for FDA‑approved PrEP in nongrandfathered commercial policies and forces plans to include certain non‑self‑administered prevention products in the outpatient prescription drug benefit when they are covered as a medical benefit.
Who It Affects
Commercial health care service plans regulated under Knox‑Keene and health insurers regulated by the California Department of Insurance, their delegated PBMs, in‑ and out‑of‑network pharmacies and pharmacists, manufacturers of PrEP/long‑acting prevention products, and enrollees in nongrandfathered plans. Medi‑Cal managed care plans are explicitly exempt.
Why It Matters
The measure removes familiar utilization and cost barriers that delay access to PrEP/PEP, shifts site‑of‑care and billing for some products from medical to pharmacy benefit, and introduces compliance and enforcement exposure for carriers and PBMs — including administrative penalties and the background of criminal liability for willful Knox‑Keene violations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 554 rewrites the way California commercial plans treat antiretroviral prevention products. At its core the bill constrains plans’ use of prior authorization and step therapy for drugs, devices, or products that are medically necessary to prevent HIV infection.
The statute includes a narrow carve‑out that permits utilization controls only when there are FDA‑approved therapeutically equivalent alternatives and the plan already provides one such alternative without controls; importantly, the bill treats long‑acting products with different durations as not therapeutically equivalent.
The bill also clarifies pharmacy practice and payment: it stops plans and contracted PBMs from blocking pharmacists from dispensing PrEP or PEP, requires plans to cover pharmacist‑furnished PrEP/PEP (including the pharmacist’s service and ordered testing), and obliges payment or reimbursement whether the pharmacist is in‑network or, when the plan offers an out‑of‑network pharmacy benefit, out‑of‑network. Separately, if a plan covers a non‑self‑administered prevention product as a medical benefit, the plan must also list that product on its outpatient prescription drug benefit so it is accessible through the pharmacy channel.On cost sharing, AB 554 demands that nongrandfathered commercial plan contracts and policies cover FDA‑approved PrEP without any enrollee cost sharing.
That zero cost‑sharing rule also applies in a narrow formulary‑exception scenario: a plan cannot impose cost sharing on a nonformulary PrEP product obtained via exception if that product is therapeutically equivalent to a formulary PrEP product that the plan covers without cost sharing. High‑deductible health plans must follow the no cost‑sharing requirement unless doing so would conflict with federal rules for HDHPs; in that case the protections kick in after the plan deductible is met.The statute is drafted as parallel amendments to the Health and Safety Code (plans under Knox‑Keene) and the Insurance Code (insurers), and it preserves standard exemptions for limited dental/vision/mental‑health‑only products and Medicare supplements.
Medi‑Cal managed care plans operating under state contracts are excluded to the extent the services are not covered under their Medi‑Cal contracts. Enforcement mechanics include the Departments’ usual administrative authority; the Knox‑Keene context means willful violations can run into criminal exposure under existing law.
The Five Things You Need to Know
Section 1342.74 (Health & Safety Code) and Section 10123.1933 (Insurance Code) each bar prior authorization and step therapy for FDA‑approved antiretroviral products used to prevent HIV, except where at least one therapeutically equivalent product is already covered without those controls.
The bill explicitly states that long‑acting products with different durations are not therapeutically equivalent, creating a legal trigger point for coverage disputes between products with differing dosing intervals.
Nongrandfathered commercial health plan contracts and policies must cover FDA‑approved PrEP without imposing any enrollee cost sharing; a nonformulary PrEP covered via exception cannot be charged cost sharing if it is therapeutically equivalent to a formulary PrEP covered without cost sharing.
When a plan covers a non‑self‑administered antiretroviral prevention product as a medical benefit, the plan must also include that product on its outpatient prescription drug benefit, potentially shifting billing from physician/clinic to pharmacy channels.
The law protects pharmacist‑furnished PrEP/PEP by prohibiting plans or contracted PBMs from blocking pharmacist dispensing and by requiring reimbursement for pharmacist services and related testing, including payment at in‑network pharmacies and out‑of‑network pharmacies when the plan offers that benefit.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Act name — PrEPARE Act of 2025
Short, formal designation naming the statute the Protecting Rights, Expanding Prevention, and Advancing Reimbursement for Equity (PrEPARE) Act of 2025. This is purely a caption but signals legislative intent to focus on access, reimbursement, and equity in HIV prevention.
Knox‑Keene obligations: utilization controls, pharmacist dispensing, and benefit alignment
Amends the plan‑law statute governing DMHC‑regulated plans. Subdivision (a) curtails prior authorization and step therapy for antiretroviral prevention products and contains the therapeutically equivalent exception; the long‑acting duration rule is embedded here, which treats differences in duration as a disqualifier for equivalence. Subdivisions (b)–(d) stop plans and delegated PBMs from preventing pharmacist dispensing and require coverage and reimbursement for pharmacist‑furnished PrEP/PEP services and testing, with pay parity across in‑network and applicable out‑of‑network pharmacy benefits. Subdivision (e) mandates no cost sharing for FDA‑approved PrEP in nongrandfathered plan contracts and prevents cost sharing for certain nonformulary exceptions that meet the therapeutic equivalence test. Subdivision (f) forces plans to list non‑self‑administered products covered as medical benefits on the outpatient prescription drug benefit; (g)–(h) supply scope exclusions (specialized plans, Medi‑Cal managed care) and high‑deductible plan caveats.
Parallel requirements for CDI‑regulated insurers
Imposes essentially the same set of requirements on health insurers: prohibition on prior authorization/step therapy subject to the same equivalence exception and long‑acting rule, pharmacist dispensing and reimbursement obligations, mandatory no cost sharing for PrEP in nongrandfathered policies, outpatient prescription benefit inclusion for certain medical‑benefit products, and the HDHP and narrow plan‑type exemptions. This creates symmetry between the regulatory regimes overseen by the Department of Insurance and the Department of Managed Health Care.
Regulator powers and hearing procedures
Grants the commissioner and department authority to implement and enforce the insurer provisions under the Administrative Procedure Act and provides for administrative penalty assessment with formal hearings conducted by administrative law judges. For Knox‑Keene plans, the underlying statutory framework retains the possibility of criminal liability for willful violations, increasing the compliance stakes.
Compatibility with federal HDHP requirements
Both codes include a carve‑in that requires compliance with the state cost‑sharing rules but defers where doing so would violate federal HDHP rules — in those cases, the zero cost‑sharing applies after the HDHP deductible is met. Practically, this requires plans to reconcile state no cost‑share mandates with federal tax‑advantaged account rules and likely to document why a deductible applies until spent.
Fiscal note: no state reimbursement required
Declares that no state reimbursement is required under Article XIII B because the only local costs arise from creating or changing crimes/infractions — a technical fiscal determination. It does not alter the underlying compliance or benefit obligations imposed on regulated carriers and plans.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People at risk of HIV seeking PrEP/PEP: They gain faster access and lower out‑of‑pocket cost when enrolled in nongrandfathered commercial plans because utilization hurdles and enrollee cost sharing are removed.
- Pharmacists and community pharmacies: The bill secures pharmacists’ ability to dispense PrEP/PEP and requires reimbursement for pharmacist‑furnished services and testing, creating a new revenue stream and operational role for pharmacy practice.
- Public health agencies and clinics focused on prevention: Lower barriers and broader pharmacist access can reduce delays in initiation and may improve uptake in underserved communities.
- Manufacturers of short‑acting PrEP and therapeutically equivalent products: If plans cannot impose utilization controls where an equivalent is covered without controls, manufacturers with a covered product may preserve market access against step therapy protocols.
- Advocacy groups focused on equity in HIV prevention: The statutory removal of cost and administrative barriers supports policy goals to reduce disparities in PrEP uptake.
Who Bears the Cost
- Commercial health care service plans and insurers: They must change utilization management, adjust formularies, and absorb claims that previously produced cost sharing, which could raise premiums or shift pharmacy‑medical payment mixes.
- Delegated PBMs and contracted pharmacy benefit managers: The law constrains PBM utilization tools, may require changes to prior authorization rules and exception workflows, and could reduce PBM leverage in formulary negotiations.
- Clinics and provider sites that administer long‑acting injectables: Forced listing of medical‑benefit products on the pharmacy benefit could shift revenue away from clinic administration and complicate site‑of‑care arrangements and reimbursement.
- Self‑insured employers (depending on ERISA contours): Employers who rely on plan design to control drug spend may face higher claims or administrative burdens, and may need to revisit benefit design and stop‑loss arrangements.
- State regulators and carriers dealing with enforcement: DMHC and the Department of Insurance will take on complaint handling, oversight, and potential adjudications, increasing administrative workload.
Key Issues
The Core Tension
The central dilemma is straightforward: AB 554 prioritizes immediate, barrier‑free access to HIV prevention products for individuals — eliminating prior authorization and enrollee cost sharing — but in doing so it constrains the tools plans and PBMs use to manage cost and ensure formulary consistency, while introducing complex operational shifts (medical‑to‑pharmacy billing, duration‑based equivalence disputes) that raise questions about who ultimately bears the increased cost and how clinical choice will be preserved.
The bill achieves access goals by removing familiar barriers, but it leaves several practical and legal questions unresolved. First, the therapeutically equivalent exception is narrow but operationally awkward: plans may still rely on the exception to impose controls so long as at least one equivalent is covered without controls.
That invites strategic formulary placement — carriers can designate a single product as the uncontrolled option and steer utilization toward it, potentially undermining the law’s access intent.
Second, the explicit rule that long‑acting products with different durations are not therapeutically equivalent creates a new litigation and negotiation axis. Manufacturers and plans will litigate or negotiate over what counts as a materially different duration (e.g., monthly vs. bimonthly vs. biannual), and clinical guidance may lag behind product commercialization.
Third, the requirement to add non‑self‑administered medical‑benefit products to the outpatient prescription formulary blurs site‑of‑care lines: it can shift costs and revenue between physician/clinic claims and pharmacy claims, complicate network access for injectables (which may require clinic administration), and require systems changes for billing and prior authorization workflows.
Finally, the zero cost‑sharing mandate and HDHP carve‑out create compliance complexity. Insurers must reconcile state mandates with federal HDHP/HSA rules and document deductible applications.
Delegated PBMs and plans will need to change exception and prior authorization processes quickly, and the combination of administrative penalties and the backdrop of criminal penalties for willful Knox‑Keene violations raises legal risk for carriers that fail to align operations — a nontrivial implementation burden given formularies, PBM contracts, and reimbursement systems that span national operations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.